A Phase 2 Study of the Effects of LY545694, an iGluR5 Antagonist, in the Treatment of Subjects With Painful Diabetic Neuropathy.
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2014
At a glance
- Drugs LY 545694; Pregabalin
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 28 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 May 2009 Planned end date changed from Jan 2010 to Jun 2010 as reported by ClinicalTrials.gov.